Gadopentetate dimeglumine (Magnevist, BAY86-4882)

DRUG5 trials

Sponsors

Bayer

Conditions

Diagnostic ImagingFibrosisHealthyKidney FailureMagnetic Resonance ImagingPeripheral Vascular DiseaseRenal Insufficiency

Phase 1

Cardiovascular Safety Study of Magnevist® Injection at Two Dose Levels and Two Injection Rates in Normal Subjects

CompletedNCT00310596

Start: 2004-01-31End: 2004-03-31Updated: 2014-12-30

Phase 3

Magnevist® Injection Enhanced MRA at Two Dose Levels Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Infrarenal Aorta and Peripheral Arteries

CompletedNCT00185276

BayerPeripheral Vascular Disease

Start: 2003-03-31End: 2004-08-31Updated: 2014-12-30

Gadobutrol Magnevist-controlled Body Study

CompletedNCT01050829

BayerMagnetic Resonance Imaging

Start: 2010-01-31End: 2011-04-30Updated: 2014-12-30

Unknown Phase

Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist

CompletedNCT00744939

BayerFibrosis, Kidney Failure, Renal Insufficiency

Start: 2008-11-30End: 2013-11-30Updated: 2014-09-22

Magnevist Post-marketing Surveillance in Japan

CompletedNCT01376739

BayerDiagnostic Imaging

Start: 2007-08-31End: 2010-06-30Updated: 2011-06-20